China's medical products administrator approved Zhuhai Rundu Pharmaceutical's (SHE:002923) marketing application for cisatracurium besylate, according to a Tuesday filing with the Shenzhen bourse.
The drug is indicated as a muscle relaxant, and could be used as an addition to anesthesia or as a sedative in intensive care, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments